# CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers

> **NCT00822809** · PHASE3 · COMPLETED · sponsor: **Neovii Biotech** · enrollment: 230 (actual)

## Conditions studied

- Cancer
- Neoplasms
- Carcinoma
- Malignant Ascites

## Interventions

- **DRUG:** Catumaxomab
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT00822809
- **Lead sponsor:** Neovii Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-11
- **Final completion:** 2011-04
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2012-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822809, "CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00822809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*